Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 231 citations
https://doi.org/10.1016/s1470-2045(18)30862-3